AIMP2-DX2 Vectors for Retinal Cell Survival in Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Retinal degenerative diseases, such as age-related macular degeneration (AMD), retinitis pigmentosa (RP), and glaucoma, result in irreversible visual impairment due to the degeneration of retinal cells, with current treatments lacking effective methods to reverse this process.
Innovation Solution
Administration of a nucleic acid molecule or recombinant vector containing an exon 2-deleted AIMP2 variant (AIMP2-DX2) to inhibit cell apoptosis and promote cell survival, potentially combined with a miR-142 target sequence, using various delivery methods to target retinal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for retinal degenerative diseases, then visual impairment is managed, but the degeneration remains irreversible and no effective reversal occurs
Solution Approach 1:
The patent identifies AIMP2 as a harmful factor that promotes retinal cell apoptosis and converts it into a beneficial target for therapy. By delivering an AIMP2-DX2 variant that inhibits AIMP2 function, the harmful apoptotic signaling is blocked, transforming the disease mechanism into a treatable condition and enabling potential reversal of retinal cell degeneration.
Solution Approach 2:
The patent modifies the AIMP2 gene by creating an exon 2-deleted variant (AIMP2-DX2) that changes its functional parameters. This variant loses the pro-apoptotic function of wild-type AIMP2 and instead exerts protective effects on retinal cells, thereby changing the biological parameter from harmful to beneficial.
2Reliability
If AIMP2-DX2 is administered to treat retinal degenerative diseases, then cell survival is promoted and vascular leakage is reduced, but the mechanism of action and delivery methods require careful design
Solution Approach 1:
The AIMP2-DX2 variant serves multiple functions simultaneously: it inhibits AIMP2-mediated apoptosis, reduces vascular leakage, prevents choroidal neovascularization, and promotes retinal cell survival. This multi-functionality simplifies the therapeutic approach by using a single agent to address multiple disease mechanisms.
Solution Approach 2:
The patent employs various delivery vectors (viral and non-viral) as intermediaries to transport the AIMP2-DX2 gene or RNA into retinal cells. These vectors act as mediators that facilitate the introduction of therapeutic material without directly participating in the biological mechanism of action.
3Reliability
If AIMP2-DX2 inhibits cell apoptosis, then retinal cell death is reduced, but the exact molecular mechanisms and target interactions require precise understanding
Solution Approach 1:
The patent extracts and identifies specific molecular targets of AIMP2-DX2, such as TRAF2 and other apoptotic pathway components. By isolating these key interaction points, the complex apoptotic signaling network is simplified into manageable targets that can be systematically studied and measured.
Solution Approach 2:
The patent employs multiple assay systems that provide feedback on AIMP2-DX2 activity, including measurements of apoptosis rates, vascular leakage, and choroidal neovascularization. This feedback enables continuous monitoring and refinement of the therapeutic mechanism.
Data Source
AI summary
Disclosed herein are methods of treating retinal degenerative diseases, comprising administering to a subject in need thereof a vector comprising AIMP2-DX2 and optionally a target sequence for miR-142.